Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending February 2009. The report serves as a notification of transactions involving a Person Discharging Managerial Responsibility (PDMR) in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure regarding insider trading activity rather than a financial performance report.
Material Changes
The filing details a specific transaction involving Dr. M. Slaoui, a Person Discharging Managerial Responsibility. On February 19, 2009, a connected person of Dr. Slaoui sold 355 ordinary shares of GlaxoSmithKline plc at a price of £11.91 per share. This sale was executed to meet tax liabilities following the vesting of a Performance Share Plan award.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. The only unusual item noted is the specific share sale by a connected person of a senior executive.
Key Facts for Investor Verification
- Transaction Date: February 19, 2009.
- Individual Involved: Dr. M. Slaoui (via a connected person).
- Transaction Type: Sale of 355 ordinary shares.
- Price per Share: £11.91.
- Purpose: To meet tax liabilities from a Performance Share Plan vesting.
- Notification Date: February 20, 2009.